Website Content Headers (2)
April 28, 2026

Configurable vs Customizable Platforms and How to Choose the Right Approach for Your Study

Clinical trial protocols are becoming more complex than ever—driven by adaptive designs, biomarker-based decision-making, decentralized elements, and advanced therapies.

But while study designs have evolved, execution technology hasn’t always kept pace.

Many sponsors rely on configurable IRT/RTSM platforms designed for simpler workflows. As complexity increases, these systems can introduce operational constraints, limit flexibility, and create challenges when protocols inevitably change.

So how do you ensure your IRT strategy can support modern trials—without sacrificing speed or control?

This white paper explores:

  • The difference between configurable and truly customizable IRT
  • Why protocol complexity is reshaping execution requirements
  • How customization can improve study resilience
  • How AI is reducing the trade-off between flexibility and speed

Recent Posts

Bayesian Methods for Oncology Studies
How Bayesian Dose-Finding Designs Can Accelerate Early-Phase Oncology Clinical Research
Everest is a Finalist for the Fierce Outsourcing Awards
Everest Clinical Research Named Finalist of Fierce Outsourcing Awards for Excellence in Client Partnership
Man analyzing data on computer screen
Who Should Own Your Clinical Study URL? A Practical Guide for Sponsors
Friedreich's Ataxia Research Alliance and Everest announce a partnership
Everest Clinical Research and the Friedreich’s Ataxia Research Alliance (FARA) Announce Biostatistics Partnership to Advance Research in Friedreich’s Ataxia
Everest is expanding to Manila Philippines
Everest Clinical Research to Expand Asia Pacific Operations with New Biometrics Team in the Philippines

Share This Post